Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
Conditions
Interventions
CR845 1.0 mg
Placebo
Locations
14
United States
Cara Therapeutics Study Site
Coronado, California, United States
Cara Therapeutics Study Site
Rialto, California, United States
Cara Therapeutics Study Site
San Francisco, California, United States
Cara Therapeutics Study Site
Colorado Springs, Colorado, United States
Cara Therapeutics Study Site
Miami, Florida, United States
Cara Therapeutics Study Site
Plantation, Florida, United States
Start Date
June 25, 2019
Primary Completion Date
June 29, 2022
Completion Date
June 29, 2022
Last Updated
July 3, 2023
Lead Sponsor
Cara Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions